Progressive Autoimmune Beta Cell Insufficiency: Occurrence in the Absence of High-Risk HLA Alleles DR3, DR4
- George S Eisenbarth, M.D., Ph.D.,
- S Srikanta, M.D.,
- Ellen Fleischnick, M.D.,
- Om P Ganda, M.D.,
- Richard A Jackson, M.D.,
- Stuart J Brink, M.D.,
- J Stuart Soeldner, M.D.,
- Edmond J Yunis, M.D. and
- Chester Alper, M.D.
- Joslin Diabetes Center, the Center for Blood Research, the Dana-Farber Cancer Institute, Brigham and Women's Hospital, New England Deaconess Hospital, and Harvard Medical School Boston, Massachusetts
- Address reprint requests to G. S. Eisenbarth, M.D., Ph.D., Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215.
Abstract
In a prospective screening program for type I diabetes mellitus, we identified a unique family in which several members (mother and three siblings) expressed an unusual set of HLA-DR alleles (DR2+, DR3/4−) and were in different phases of immunologically mediated islet beta cell dysfunction. Immunologic and/or clinical manifestations of type I diabetes were absent in all siblings not sharing both HLA haplotypes in common with the proband. This article illustrates: the clinical utility of prospective family screening for predictive markers, such as islet cell antibodies, progressive autoimmune beta cell destruction can occur in the absence of the “high-risk” alleles HLA-DR3 and DR4, and HLA identity with the proband, rather than specific HLA alleles, i.e., presence of DR3, DR4 and absence of DR2, is an essential factor.
- Copyright © 1985 by the American Diabetes Association











